Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from China Isotope & Radiation Corp. ( (HK:1763) ).
China Isotope & Radiation Corporation has disclosed that its non-wholly-owned subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has been ordered by Chinese tax authorities to pay RMB188 million in additional corporate income tax, value-added tax and other taxes for the period from 1 January 2021 to 31 December 2024, plus late payment surcharges, bringing the total tax settlement to RMB271 million. The tax adjustment, which centers on sales expenses and abnormal inventory losses at Headway and carries no administrative penalties, has already been fully paid and is expected to reduce the company’s profit attributable to equity shareholders in 2025 by about RMB130 million, with final impact subject to independent audit review; the company says it will strengthen internal management and warns investors to exercise caution as it may issue further updates.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a Hong Kong–listed joint stock company incorporated in the People’s Republic of China, operating in the isotope and radiation sector, with its business involving radiopharmaceuticals and related technologies through various subsidiaries, including Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
Average Trading Volume: 361,013
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.49B
For a thorough assessment of 1763 stock, go to TipRanks’ Stock Analysis page.